Pathstone Holdings
NVO

Pathstone Holdings’s Novo Nordisk NVO Stock Holding History

Pathstone Holdings’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.2M Buy
358,915
+33,228
+10% +$1.43M 0.05% 233
2026
Q1 		$12M Sell
325,687
-19,366
-6% -$918K 0.05% 288
2025
Q4 		$17.6M Buy
345,053
+43,507
+14% +$2.22M 0.07% 196
2025
Q3 		$16.7M Buy
301,546
+21,387
+8% +$1.25M 0.06% 208
2025
Q2 		$19.3M Sell
280,159
-59,969
-18% -$4.08M 0.08% 175
2025
Q1 		$23.7M Buy
340,128
+65,227
+24% +$5.39M 0.1% 144
2024
Q4 		$23.6M Sell
274,901
-15,328
-5% -$1.66M 0.1% 133
2024
Q3 		$34.6M Buy
290,229
+734
+0.3% +$97.9K 0.15% 102
2024
Q2 		$41.3M Buy
289,495
+12,207
+4% +$1.62M 0.19% 85
2024
Q1 		$35.6M Buy
277,288
+122,229
+79% +$14.6M 0.17% 92
2023
Q4 		$16.1M Buy
+155,059
New +$15.3M 0.09% 170

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Pathstone Holdings's NVO Position: Q2 2026 in Review

Pathstone Holdings increased its Novo Nordisk (NVO) stake by 10% in Q2 2026, buying an estimated $1.43M and bringing the position to 358,915 shares worth $17.2M. The position accounts for 0.05% of the portfolio, ranked #233.

Pathstone Holdings first reported a position in NVO in Q4 2023 and has held it in 11 quarters since. The position peaked at $41.3M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Pathstone Holdings held 358,915 shares of Novo Nordisk worth $17.2M as of Q2 2026.
  • Pathstone Holdings bought 33,228 Novo Nordisk shares in Q2 2026, an estimated $1.43M.
  • Novo Nordisk made up 0.05% of Pathstone Holdings's portfolio in Q2 2026, its #233 holding.
  • Pathstone Holdings first reported a position in Novo Nordisk in Q4 2023 and has held it in 11 quarters since.
  • Pathstone Holdings's Novo Nordisk position peaked at $41.3M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.